| Name | Title | Contact Details |
|---|
The mission of Life Line Screening is to make people aware of an undetected health problem and encourage them to seek follow up care with their physician. We are dedicated to providing the highest quality preventive screenings at an affordable rate.
Healthcare Management Partners, LLC is a hospital and healthcare services management firm. HMP is a firm led by a team of C-Level healthcare executives that quickly define and solve problems to produce exceptional results for healthcare organizations and their stakeholders. With its extensive experience, Financial Modeling and Data Analysis Tools and action-based business model, HMP provides senior executive led management, financial advisory and litigation support services to hospitals and other healthcare organizations and their creditors, investors and business partners. The complex and ever-changing nature of the healthcare markets can test even the strongest organizations. Healthcare Management Partners serves as advisor to hospitals and other healthcare providers facing strategic decisions directly impacting current or future financial performance. HMP also frequently serves banks, bond holders, private equity firms or committees of unsecured creditors and their legal and accounting advisors in conjunction with complex business transactions or restructurings involving healthcare providers. We provide creditor advisory and operational and financial due diligence. Unlike many of our competitors, every financial advisory services engagement is led on the ground by experienced C-Level healthcare executives.
Pioneer Surgical is a leading innovator in the design and manufacture of spinal and orthopedic implants and instruments.
Aaramark Healthcare is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona’s lead program is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Sanfilippo types A and B are anticipated to begin in 2015.